Draft Guidance on Deflazacort

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Deflazacort

**Dosage Form; Route:** Tablet; oral

**Recommended Studies:** Two studies

1. **Type of study:** Fasting  
   **Design:** Single-dose, two-way crossover in-vivo  
   **Strength:** 36 mg  
   **Subjects:** Males and non-pregnant, non-lactating females, general population.  
   **Additional Comments:** None

2. **Type of study:** Fed  
   **Design:** Single-dose, two-way crossover in-vivo  
   **Strength:** 36 mg  
   **Subjects:** Males and non-pregnant, non-lactating females, general population.  
   **Additional Comments:** None

**Analyte to measure (in appropriate biological fluid):** 21-desacetyldeflazacort (active metabolite) in plasma

**Bioequivalence based on (90% CI):** 21-desacetyldeflazacort

**Waiver request of in-vivo testing:** 6 mg, 18 mg, and 30 mg based on (i) acceptable bioequivalence studies on the 36 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths.

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).

*Recommended Oct 2017*